Design, Synthesis and In Vitro Evaluation of Novel Anti-HIV 3-Pyrazol-3-yl-Pyridin-2-One Analogs

Background: Natural products have shown potent anti-HIV activity, but some of these also possess toxicity. The pharmacophoric fragments of these natural products have scope of combination with other pharmacophoric fragment and derivatization to reduce toxicity and increase the potency. Combination of natural product fragments from different classes of anti-HIV compounds may lead to a new class of potent anti-HIV agents. Objective: Design, in silica prediction of drug-likeness, ADMET properties and synthesis of pyrazol-pyridones. Evaluation of the anti-HIV-1 activity of synthesized pyrazol-pyridones. Methods: Pyrazol-pyridones were designed by combining reported anti-IVIV pharmacophoric fragments. Designed molecules were synthesized after in silico prediction of drug-likeness and ADMET properties. Compounds were evaluated for activity against HIV-1(VB59) and HIV-1(UG070). Results: QED value of designed pyrazol-pyridones was greater than the known drug zidovudine. The designed compounds were predicted to be noncarcinogenic and nonmutagenic in nature. Seventeen novel pyrazol-pyridones were synthesized with good yield. Compound 6q and 61 showed activity with IC50 values 6.14 mu M and 15.34 mu M against HIV-1(VB59) and 16.21 mu M and 18.21 mu M against HIV-1(UG070), respectively. Conclusion: Compound 6q was found to be most potent among the synthesized compounds with a therapeutic index of 54.31 against HIV-1(VB59). This is the first report of anti-HIV-1 activity of pyrazol-pyridone class of compounds. Although the anti-HIV-1 activity of these compounds is moderate, this study opens up a new class for exploration of chemical space for anti-HIV-1 activity.